At a glance
ClinicalIndex Comparison RecordN/ACompleted· 426 enrolled
Drug / intervention
Observationalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis
Community and Patient Preference Research Pty Ltd·observational·Posted Dec 6, 2021·Updated Apr 12, 2024
In Brief
An observational study evaluating Observational for Allergic Rhinitis. Completed, enrolled 426 participants across 1 site.
Detailed Summary
The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesAustralia
CollaboratorsSeqirus, Glenmark Pharmaceuticals S.A.
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedDec 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedDec 6, 2021
Enrollment StartNov 8, 2021
Primary CompletionFeb 27, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.6 years ago
Interventions
Observationalother
In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.